PERCIST · Oncologia
PERCIST PERCIST PET response criteria
vigenteAssesses tumor metabolic response on FDG PET.
Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.
Procedência e vigência
- Órgão emissor
- Nuclear medicine consensus
- Versão
- 1.0
- Ano
- 2009
- Família
- léxico
- Tipo de lógica
- flat
- Modalidade
- PET
- Fonte primária
- From RECIST to PERCIST: evolving considerations for PET response criteria · doi:10.2967/jnumed.108.057307
- Última verificação
- 2026-06-22
- Última checagem
- 2026-06-22
Lógica de decisão
Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.
Mostrar a lógica estruturada (JSON)
{
"categories": [
"CMR",
"PMR",
"SMD",
"PMD"
]
}Categorias num relance
| Cat. | Significado | Conduta | Risco | Fonte |
|---|---|---|---|---|
| CMR | Complete metabolic response Complete Metabolic Response: FDG uptake in the measurable target lesion resolves completely so that it falls below mean liver activity and is indistinguishable from surrounding background blood-pool, with no new FDG-avid lesions typical of cancer. | — | — | okfonte PMC4073366 (Ding et al., 'PET/CT evaluation of response to chemotherapy in NSCLC: PERCIST versus RECIST') Methods, 'Response evaluation methods' ('complete resolution of 18F-FDG uptake within the measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels with no new 18F-FDG-avid lesions'); cross-checked PMC5542859 Table 1 |
| PMR | Partial metabolic response Partial Metabolic Response: a reduction of at least 30% in the SUL peak of the target tumor (with a minimum absolute decline of about 0.8 SUL units), referenced to baseline, and no new lesions. | — | — | okfonte PMC4073366 Methods 'Response evaluation methods' ('reduction of a minimum of 30% in the target tumor 18F-FDG SULpeak'); >=0.8 SUL absolute minimum and no-new-lesion requirement cross-checked PMC5542859 Table 1 ('Decrease of SUL by >=30% and at least 0.8 SUL units difference ... no new FDG-avid lesions') |
| SMD | Stable metabolic disease Stable Metabolic Disease: change in SUL peak that does not reach the thresholds for CMR, PMR, or PMD (i.e. an increase or decrease of less than 30%). | — | — | okfonte PMC4073366 Methods 'Response evaluation methods' ('disease other than CMR, PMR, or progressive metabolic disease'); the <30% change framing cross-checked PMC5542859 Table 1 ('Increase or decrease of SUL by less than 30%') |
| PMD | Progressive metabolic disease Progressive Metabolic Disease: an increase of at least 30% in SUL peak (with a minimum absolute rise of about 0.8 SUL units), or a visible increase in the extent of FDG uptake, or the appearance of new FDG-avid lesions typical of cancer. | — | — | okfonte PMC4073366 Methods 'Response evaluation methods' ('a 30% increase in 18F-FDG SULpeak or advent of new 18F-FDG-avid lesions that are typical of cancer'); >=0.8 SUL absolute minimum cross-checked PMC5542859 Table 1 ('SUL increase by at least 30% and increase by at least 0.8 SUL units ... or development of new lesion(s)') |
Histórico de versões
Nenhum evento de versão registrado.
Quickstart da APIGET /api/v1/systems/percistaberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/percist"